Attached files
| file | filename |
|---|---|
| 10-Q - EDGE THERAPEUTICS, INC 10-Q 6-30-2016 - PDS Biotechnology Corp | form10q.htm |
| EX-31.1 - EXHIBIT 31.1 - PDS Biotechnology Corp | ex31_1.htm |
| EX-31.2 - EXHIBIT 31.2 - PDS Biotechnology Corp | ex31_2.htm |
| EX-32.1 - EXHIBIT 32.1 - PDS Biotechnology Corp | ex32_1.htm |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Edge Therapeutics, Inc. (the “Company”), on Form 10-Q for the quarter ended June 30, 2016 (the “Report”), I, Andrew J. Einhorn, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
| (1) | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Dated: August 3, 2016
|
/s/ Andrew J. Einhorn
|
|
Andrew J. Einhorn,
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer)
|